Greg Kunst

Company: Aurion Biotech

Job title: President & Chief Executive Officer

Seminars:

Focusing in on the Regulatory Landscape for Allogeneic Cell Therapies 3:00 pm

Examining acceptance criteria expectations around gene editing, toxicity, and potency assays Highlighting importance of early CMC work to enable efficient manufacturing scale-up for allogeneic products Evaluating opportunities to align global regulatory perspectives on allogeneic therapiesRead more

day: Day Two